Photocure ASA

Regulatory Filings • May 22, 2015

PHOTOCURE ANNOUNCES EXCLUSIVE PARTNER FOR HEXVIX® IN AUSTRALIA AND NEW ZEALAND

PHOTOCURE ANNOUNCES EXCLUSIVE PARTNER FOR HEXVIX® IN AUSTRALIA AND NEW ZEALAND

Oslo, Norway, 22 May,  2015: Photocure ASA (OSE: PHO), a specialty

pharmaceutical company focused on photodynamic technologies in dermatology and

cancer, announces today the appointment of Juno Pharmaceuticals as their

exclusive distributor for the registration and commercialization of Hexvix in

Australia and New Zealand. Hexvix is Photocure's flagship product to aid in the

diagnosis and management of bladder cancer.

Under the terms of the agreement, Photocure will receive EUR500,000 in milestone

payments for the rights to Hexvix in the territory, of which Photocure has

received EUR250 000.

Juno, who will fund all costs to secure regulatory approval, will begin the

filing process immediately. . During the review process, Juno Pharmaceuticals

will initiate the preparations for the launch of Hexvix in Australia and New

Zealand. The market potential in the territory is estimated to be similar to the

potential in the Nordics, where Photocure commercializes Hexvix with its own

sales team.

Kjetil Hestdal, President & CEO of Photocure, said: "We are happy to report that

Hexvix commercialization is progressing well and we continue to expand into new

territories to ensure patients and Urologists have access to the most optimal

treatment for the diagnosis and management of bladder cancer. We are pleased to

have secured Juno Pharmaceuticals as our new distribution partner in Australia

and New Zealand with their strong and experienced team".

For further information, please contact:

Photocure

President & CEO Kjetil Hestdal

Tel: + 47 913 19 535, Email: kh@photocure.no

CFO Erik Dahl

Tel: +47 50 55 000, Email: ed@photocure.no

About Photocure ASA

Photocure ASA, headquartered in Oslo, Norway, is a specialty pharmaceutical

company and world leader in photodynamic technology. Based on our unique

proprietary Photocure Technology(®) platform, Photocure develops and

commercializes highly selective and effective solutions in disease areas with

high unmet medical need, such as bladder cancer, HPV and precancerous cervical

lesions, colorectal cancer and skin conditions. Our aim is to provide solutions

that can improve health outcomes for patients worldwide. Photocure is listed on

the Oslo Stock Exchange (OSE: PHO). Information about Photocure is available at

www.photocure.com.

About Hexvix(®)/Cysview(®)

Hexvix(®)/Cysview(®) (hexaminolevulinate hydro-chloride) is an innovative

breakthrough technology in the diagnosis and management of non-muscle-invasive

bladder cancer. It is designed to selectively target malignant cells in the

bladder and induce fluorescence during a cystoscopic procedure using a blue-

light enabled cystoscope. Using Hexvix(®)/Cysview(®) as an adjunct to standard

white-light cystoscopy enables the urologist to better detect and remove

lesions, leading to a reduced risk of recurrence. Hexvix(®)/Cysview(®) is

approved in Europe and the USA.

About Juno Pharmaceuticals

Juno Pharmaceuticals is a privately held global health care company dedicated to

introducing a range of innovative pharmaceutical products. Juno Pharmaceuticals

was founded in 2012 by a group of experienced international pharmaceutical

executives and are a fast growing global specialty pharmaceutical company. Our

product portfolio and pipeline covers a broad spectrum of therapeutic areas and

formats including oral solid dosages, injectable, suspensions, ophthalmic

solutions, creams and patches. With a primary focus on the hospital market

channel, Juno has access to a range of presentations across multiple therapeutic

areas including biosimilar products. An extensive global network of

manufacturers allows us to source niche, lifesaving products for our customers.

Juno operates in the Australian, Canadian, Polish and United Kingdom markets.

All trademarks mentioned in this release are protected by law and are registered

trademarks of Photocure ASA.

This information is subject of the disclosure requirements acc. to §5-12 vphl

(Norwegian Securities Trading Act)

[HUG#1923395]